MSLN and breast cancer: Taken as a whole, our study demonstrates that the combined use of Carboplatin, Paclitaxel and MSLN inhibition may synergistically inhibit breast cancer liver metastasis, offering therapeutic benefit to TNBC patients with liver metastasis.